EUVIMEDEUVIMED entdecken
ÜbersichtsarbeitOpen Access · CC BY 4.0

Targeted Therapy for Cancers: From Ongoing Clinical Trials to FDA-Approved Drugs

Ha Yeong Choi, Ji-Eun Chang iD

International Journal of Molecular Sciences · 03.09.2023 · 24 (17) · 13618

DOI: 10.3390/ijms241713618 ↗

Kurz gefasst

Übersichtsarbeit in der Zeitschrift International Journal of Molecular Sciences, online erschienen am 03.09.2023. Verfasst von Ha Yeong Choi und 1 weiteren Autor:innen. Beteiligte Einrichtung: College of Pharmacy, Dongduk Women's University, Seoul 02748, Republic of Korea. Hauptthemen laut MEDLINE: Prostatic Neoplasms, Lung Neoplasms, Colonic Neoplasms. Die Arbeit wurde bisher 134-mal zitiert (Crossref) und nennt 150 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: National Research Foundation of Korea.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

The development of targeted therapies has revolutionized cancer treatment, offering improved efficacy with reduced side effects compared with traditional chemotherapy. This review highlights the current landscape of targeted therapy in lung cancer, colorectal cancer, and prostate cancer, focusing on key molecular targets. Moreover, it aligns with US Food and Drug Administration (FDA)-approved drugs and drug candidates. In lung cancer, mutations in the epidermal growth factor receptor (EGFR) and anaplastic lymphoma kinase (ALK) gene rearrangements have emerged as significant targets. FDA-approved drugs like osimertinib and crizotinib specifically inhibit these aberrant pathways, providing remarkable benefits in patients with EGFR-mutated or ALK-positive lung cancer. Colorectal cancer treatment has been shaped by targeting the vascular endothelial growth factor (VEGF) and EGFR. Bevacizumab and cetuximab are prominent FDA-approved agents that hinder VEGF and EGFR signaling, significantly enhancing outcomes in metastatic colorectal cancer patients. In prostate cancer, androgen receptor (AR) targeting is pivotal. Drugs like enzalutamide, apalutamide, and darolutamide effectively inhibit AR signaling, demonstrating efficacy in castration-resistant prostate cancer. This review further highlights promising targets like mesenchymal-epithelial transition (MET), ROS1, BRAF, and poly(ADP-ribose) polymeras (PARP) in specific cancer subsets, along with ongoing clinical trials that continue to shape the future of targeted therapy.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Prostatic NeoplasmsLung NeoplasmsColonic NeoplasmsUnited StatesMaleHumansVascular Endothelial Growth Factor AProtein-Tyrosine KinasesProto-Oncogene ProteinsErbB Receptors

Stichwörter der Autor:innen

FDA-approved drugscancer targeted therapyclinical trialscolorectal cancerlung cancerprostate cancer

Substanzen

Vascular Endothelial Growth Factor AProtein-Tyrosine KinasesProto-Oncogene ProteinsErbB Receptors

Autor:innen und Institutionen

  • College of Pharmacy, Dongduk Women's University, Seoul 02748, Republic of Korea.

ORCID-Profile: Ji-Eun Chang

Förderung

  • National Research Foundation of Korea

Zitieren

APA

Choi, H. Y., & Chang, J. E. (2023). Targeted Therapy for Cancers: From Ongoing Clinical Trials to FDA-Approved Drugs. International Journal of Molecular Sciences, 24(17), 13618. https://doi.org/10.3390/ijms241713618

Vancouver

Choi HY, Chang JE. Targeted Therapy for Cancers: From Ongoing Clinical Trials to FDA-Approved Drugs. International Journal of Molecular Sciences. 2023;24(17):13618. doi:10.3390/ijms241713618

BibTeX
@article{Choi2023,
  author = {Choi, Ha Yeong and Chang, Ji-Eun},
  title = {Targeted Therapy for Cancers: From Ongoing Clinical Trials to FDA-Approved Drugs},
  journal = {International Journal of Molecular Sciences},
  year = {2023},
  volume = {24},
  number = {17},
  pages = {13618},
  doi = {10.3390/ijms241713618}
}
Kostenlos starten →